Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv mecarbil IV infusion in acute heart failure with left ventricular systolic dysfunction
NL-OMON37556Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omecamtiv mecarbil in Acute Heart Failure (AHF) and heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Amgen. Primary endpoint: Primary dyspnea responder endpoint. Started Jun 2012; status: active, not recruiting.
02
Drugs
omecamtiv mecarbil
03
Conditions
Acute Heart Failure (AHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON37556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37556.